Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mibampator in Alzheimer's Disease
NCT00051909Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Mibampator with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 11 weeks. Started Nov 2002; status: completed.
02
Drugs
mibampator
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00051909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051909.